News
OGN
13.34
-0.07%
-0.01
Weekly Report: what happened at OGN last week (0518-0522)?
Weekly Report · 6d ago
Deep value mid-caps: 10 names trading at single-digit forward P/Es
Seeking Alpha · 05/18 11:39
Weekly Report: what happened at OGN last week (0511-0515)?
Weekly Report · 05/18 09:16
Organon to present new research at ISPOR 2026
TipRanks · 05/15 11:46
Organon to Present New Research on Access and Value at ISPOR 2026
Barchart · 05/15 06:30
Weekly Report: what happened at OGN last week (0504-0508)?
Weekly Report · 05/11 09:15
Insider trades: Intel, Bank of America, and Pinterest among notable names
Seeking Alpha · 05/09 15:03
Top Organon Executive Makes Bold Move With Major Stock Purchase
TipRanks · 05/08 02:09
Assessing Organon (OGN) Valuation After A Sharp Recent Share Price Move
Simply Wall St · 05/07 17:57
Thursday 5/7 Insider Buying Report: OGN, TENB
NASDAQ · 05/07 17:34
Here are the major earnings before the open Thursday
Seeking Alpha · 05/06 22:00
Is It Time To Reassess Organon (OGN) After Its Sharp Recent Share Price Surge?
Simply Wall St · 05/06 13:44
MaxLinear is the best performing mid cap stock
Seeking Alpha · 05/05 15:53
Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?
PR Newswire · 05/04 18:55
Organon & Co is the best performing healthcare stock in April
Seeking Alpha · 05/04 11:17
Weekly Report: what happened at OGN last week (0427-0501)?
Weekly Report · 05/04 09:14
Key deals this week: Organon, ARC Resources, Nebius, Eli Lilly and more
Seeking Alpha · 05/03 15:15
Organon Buyout And POHERDY Approval Shape Returns And Valuation Outlook
Simply Wall St · 05/02 19:34
Trending stocks this week as Big Tech earnings lift markets amid Fed pause
Seeking Alpha · 05/02 12:06
An April To Remember For Stocks
Seeking Alpha · 05/02 00:10
More
Webull provides a variety of real-time OGN stock news. You can receive the latest news about ORGANON & CO through multiple platforms. This information may help you make smarter investment decisions.
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.